Use of inhibitors of adam12 as adjuvants in tumor therapies
Номер патента: EP3410849A1
Опубликовано: 12-12-2018
Автор(ы): Lucie Peduto, Selene DI CARLO
Принадлежит: Institut National de la Sante et de la Recherche Medicale INSERM, Institut Pasteur de Lille
Опубликовано: 12-12-2018
Автор(ы): Lucie Peduto, Selene DI CARLO
Принадлежит: Institut National de la Sante et de la Recherche Medicale INSERM, Institut Pasteur de Lille
Реферат: It has been discovered that disrupting the stromal capsule restores a better vasculature/tumor perfusion and improve T cells infiltration inside the core of a melanoma. The invention relates to the use of drugs or immunoconjugates that target the transmembrane protease ADAM12 and deplete the cells that express it. Since ADAM12 protein is specifically expressed by stromal cells of the tumor stromal capsule and around vessels in models for prostate cancer, neuroendocrine pancreatic cancer and melanoma, an ADAM12 inhibitor is useful in anti-tumor therapies as an adjuvant. The invention encompasses methods, compositions, and kits containing ADAM12 inhibitors for use in the depletion of ADAM12+ stromal cells in cancer patient, particularly together with ant-tumor compounds and treatments.
Use of inhibitors of ADAM12 as adjuvants in tumor therapies
Номер патента: US11780934B2. Автор: Lucie Peduto,Selene DI CARLO. Владелец: Institut National de la Sante et de la Recherche Medicale INSERM. Дата публикации: 2023-10-10.